Skip to main content
Fig. 1 | Journal of Hematology & Oncology

Fig. 1

From: Emerging therapies for non-small cell lung cancer

Fig. 1

Reported acquired resistance to osimertinib and corresponding potential strategies. Preclinical and clinical data consisted of EGFR-dependent/independent resistant mechanism to osimertinib were included. Additional corresponding TKI with osimertinib may be available in other oncogene-driven resistance, and whether checkpoint inhibitors would be beneficial in pan-negative patients after osimertinib or treatment failure was yet to be answered. TBP, treatment beyond progression

Back to article page